ZYBT - Zhengye Bio Quarterly Revenue Growth

Symbol and logo of brand Jilin Zhengye Biotechnology (ZYBT)

The QoQ revenue growth rate reflects sales dynamics, where -13.70 represents the latest metric reading. Zhengye Biotechnology (ZYBT) relies on its own vaccine production lines, outsourcing only logistics. Professional management effectively navigates regulatory barriers within the biotech sector. The company's innovative developments are critical for China's food security and receive state support.

ZYBT (Jilin Zhengye Biotechnology) Quarterly Sales Growth history from 01/08/2025 to 11/20/2026

Financial and market metric breakdowns for Jilin Zhengye Biotechnology (ZYBT)

- share price and expert price forecast:
- cash and cash flow data:
Basic company analysis:ZYBT - Zhengye Biotechnology
Mass-produced product of Zhengye Biotechnology Co., Ltd.

A qualitative asset assessment requires separating fundamental trends from market noise. This indicator measures quarterly sales expansion rates, allowing investors to identify business cycle inflection points. Analyzing the quarterly revenue growth rate helps determine the actual scaling speed of operational activities. For Zhengye Biotechnology (ZYBT), this trend directly reflects the demand for specialized livestock vaccines.